Neighborhoods Rehab & Skilled Nursing By Tigerplac | |
3003 Falling Leaf Court, Columbia, Missouri 65201 | |
(573) 256-4620 | |
Name | Neighborhoods Rehab & Skilled Nursing By Tigerplac |
---|---|
Location | 3003 Falling Leaf Court, Columbia, Missouri |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 120 |
Occupancy Rate | 58.83% |
Medicare ID (CCN) | 265840 |
Legal Business Name | Tiger Place, Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1609263540 |
Address | 3003 Falling Leaf Ct, Columbia, MO 65201 |
Phone Number | 573-355-9684 |
News Archive
Depression was linked with an increased risk of peripheral artery disease (PAD) in a study of more than one thousand men and women with heart disease conducted by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.
Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.
ImThera Medical, Inc., a privately held global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its THN3 Clinical Study.
BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the U.S. and Xiapex in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.
› Verified 7 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Depression was linked with an increased risk of peripheral artery disease (PAD) in a study of more than one thousand men and women with heart disease conducted by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.
Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.
ImThera Medical, Inc., a privately held global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its THN3 Clinical Study.
BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the U.S. and Xiapex in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.
› Verified 7 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 17.28 | 14.46 |
Percentage of long-stay residents who lose too much weight | 10.46 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 44.44 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.8 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.13 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.89 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 4.19 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 91.62 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 12.23 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 80.22 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 6.91 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 35.61 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.57 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 9.21 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.96 | 95.98 |
Percentage of short-stay residents who made improvements in function | 75.38 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 83.62 | 82.93 |
News Archive
Depression was linked with an increased risk of peripheral artery disease (PAD) in a study of more than one thousand men and women with heart disease conducted by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.
Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.
ImThera Medical, Inc., a privately held global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its THN3 Clinical Study.
BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the U.S. and Xiapex in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.
› Verified 7 days ago
Villa At Blue Ridge, The Location: 701 Blue Ridge Road, Columbia, Missouri 65201 Phone: (573) 474-6111 | |
Lenoir Health Care Center Location: 3850 Cartwright Lane, Columbia, Missouri 65201 Phone: (573) 876-5800 | |
Columbia Manor Care Center Location: 2012 Nifong Boulevard, Columbia, Missouri 65201 Phone: (573) 449-1246 |